Woman researcher looking at test tube samples.

Clinical Research

Today’s Commitment. Tomorrow’s Cure.

The Clinical Research Program at Prism Health North Texas was created after the Peabody Health Center was awarded a seven-year grant to be a network clinical research site (CRS) of National Institutes of Health’s (NIH) AIDS Clinical Trials Group (ACTG) in 2006. In 2007, the organization began to partner with pharmaceutical companies to participate in industry-sponsored clinical trials. The Clinical Research Program has focused on research studies for HIV treatment, HIV Prevention, Hepatitis C Treatment, TB Prevention, and HIV co-morbidities such as HIV and Aging, HIV-associated neurocognitive disorders, and cardiovascular disease in patients living with HIV.

Feature Study - COVID-19 Vaccine

Help Find a Vaccine for COVID-19

We’re looking for:

  • Adults aged 18 and older
  • People who are more likely to be exposed to COVID-19, including:
    • People with underlying medical conditions.
    • People with greater chances of exposure at their job.
    • People who live or work in elder-care facilities.
    • People over age 65.
    • People who work in jails or prisons.
    • People from racial and ethnic groups that have been impacted in greater numbers by the epidemic, such as African Americans, Latinx, and Native Americans.

If you decide to join a COVID-19 prevention study, you will be compensated for your time. You CANNOT get infected with SARS-CoV-2 or get COVID-19 illness from the study vaccine. Visit www.CoronavirusPreventionNetwork.org for more information about the study.

Steps to Be a Volunteer for the COVID-19 Vaccine Study

1 – Download and review the Consent Form which includes details and requirements for participation.

Download Consent Form

2 – If you are still interested after reviewing the Consent Form, please fill out the online contact form.

Complete Online Contact Form

Black female provider with tablet talking to Asian female patient

Current Research Studies

COVID-19 Vaccine Study
  • AZD1222 is an investigational vaccine being developed by AstraZeneca to prevent COVID-19, the disease caused by the SARS-CoV-2 virus.

The vaccine is based on a weakened version of a common cold (adenovirus) virus. The adenovirus vaccine has been changed so that it can’t replicate inside your body. It presents part of the COVID-19 spike protein to the body so that an immune response can be made to it. The purpose of the study is to test how well the investigational vaccine works at preventing COVID-19 disease and how safe it is.

HIV Treatment Studies

Switch Studies for those suppressed on current treatment:

  • TMC114FD2HTX4004: A Study of Symtuza (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)
  • M19-939999: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1

Switch studies for those who have trouble taking medication or with medication resistance:

  • GS-US-200-4625: Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination with an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV with Multidrug Resistance (CAPELLA)

STI Studies
  • 248C1: Clinical Evaluation of the Xpert Xpress Chlamydia & Gonorrhea Test in Male Urine and Extragenital Specimens



Research Publications

  • Comparable Viral Decay with Initial Dolutegravir Plus Lamivudine Versus Dolutegravir-Based Triple Therapy // Read More →
  • Hepatic Steatosis in People Living with HIV: Effect of Sex and Race/Ethnicity // Read More →


Be a Study Participant

PHNTX is honored to participate in the AIDS Clinical Trials Group, one of the largest HIV clinical trials organizations in the world, and is currently enrolling for the research studies listed above. If you are interested in being a part of a study, please contact our Clinical Research Department at research@prismntx.org.

Contact Clinical Research
Female Provider Drawing Blood from Male Patient

Community Advisory Board

The Research Program has an active Community Advisory Board (CAB) dedicated to community outreach and peer education. The CAB is made up of five men and two women who are passionate about HIV research, treatment, and prevention. The CAB meets every other month and reviews studies in the early phase of development to provide community feedback on the study’s design, which helps the sponsor improve study objectives, potential recruitment, and participant retention. The CAB also provides input on ways to recruit participants and keep them engaged while participating in a study.